GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » EBITDA Margin %

Yumanity Therapeutics (FRA:8IY) EBITDA Margin % : -239.12% (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Yumanity Therapeutics's EBITDA for the three months ended in Sep. 2022 was €-3.39 Mil. Yumanity Therapeutics's Revenue for the three months ended in Sep. 2022 was €1.42 Mil. Therefore, Yumanity Therapeutics's EBITDA margin for the quarter that ended in Sep. 2022 was -239.12%.


Yumanity Therapeutics EBITDA Margin % Historical Data

The historical data trend for Yumanity Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics EBITDA Margin % Chart

Yumanity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
EBITDA Margin %
- -794.44 -459.71

Yumanity Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -572.59 -1,300.30 -1,244.56 -289.99 -239.12

Competitive Comparison of Yumanity Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Yumanity Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yumanity Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's EBITDA Margin % falls into.



Yumanity Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Yumanity Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2021 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-32.727/7.119
=-459.71 %

Yumanity Therapeutics's EBITDA Margin % for the quarter that ended in Sep. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2022 )/Revenue (Q: Sep. 2022 )
=-3.386/1.416
=-239.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yumanity Therapeutics  (FRA:8IY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Yumanity Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Yumanity Therapeutics (FRA:8IY) Business Description

Traded in Other Exchanges
N/A
Address
40 Guest Street, Suite 4410, Boston, MA, USA, 02135
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines